Picture of Theratechnologies logo

THTX Theratechnologies Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapNeutral

Momentum

Relative Strength (%)
1m-4.68%
3m-2.19%
6m-28.64%
1yr-72.47%
Volume Change (%)
10d/3m-52.13%
Price vs... (%)
52w High-66.83%
50d MA-0.33%
200d MA-15.33%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-38.37%
Return on Equityn/a
Operating Margin-10.7%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Nov 202430th Nov 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Theratechnologies EPS forecast chart

Profile Summary

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

Directors

Last Annual
November 30th, 2023
Last Interim
February 29th, 2024
Incorporated
February 1st, 1995
Public Since
December 21st, 1993
No. of Employees
89
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
us flag iconNASDAQ Capital Market
Shares in Issue
45,980,768

THTX Share Price Performance

Upcoming Events for THTX

Q2 2024 Theratechnologies Inc Earnings Release

Q3 2024 Theratechnologies Inc Earnings Release

Similar to THTX

Picture of 60 Degrees Pharmaceuticals logo

60 Degrees Pharmaceuticals

us flag iconNASDAQ Capital Market

Picture of Aadi Bioscience logo

Aadi Bioscience

us flag iconNASDAQ Capital Market

Picture of Acasti Pharma logo

Acasti Pharma

us flag iconNASDAQ Capital Market

Picture of Agriforce Growing Systems logo

Agriforce Growing Systems

us flag iconNASDAQ Capital Market

Picture of Aptorum logo

Aptorum

us flag iconNASDAQ Capital Market

FAQ